OVERVIEW of the TANGO Study

The hallmark of Alzheimer’s disease is the development of plaques and tangles of certain types of proteins in the brain. The TANGO Study is evaluating the safety, dosing, and effectiveness of an investigational drug to see if it has the potential to be a treatment in people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.

The investigational drug is designed to target the tau protein, which is one of the key proteins that build up in the brain and cause tangles in people with Alzheimer’s disease. Researchers are evaluating the investigational drug to see if when taken early, may potentially help reduce the spread of tau in the brain—and if it may potentially slow the progress of the disease.

We’re looking for 528 patients from around the world to take part in this research effort.

Key features of this Phase 2 study

age

For men and women
50–80 years old*

2_IN_3

2-in-3 participants will
receive investigational drug

1_IN_3

1-in-3 participants
will receive placebo

fluid

Investigational drug or placebo given by intravenous infusions (a slow injection into a vein) every four weeks

calender

Optional potential
long-term extension study

*Please note that other eligibility criteria apply

WHO WE’RE LOOKING FOR

brain

People diagnosed with MCI due to Alzheimer’s disease or mild Alzheimer’s disease

heartbeat

Are otherwise healthy; have no other significant / uncontrolled medical issues

thinking

People who believe they are experiencing frequent memory problems beyond normal aging (undiagnosed patients)

partner

Must be able to have a study partner who can attend certain appointments and provide information about the study participant’s health